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Hypertensive emergencies are diagnosed if there is a systolic 
blood pressure higher than 180 mmHg or a diastolic blood 
pressure higher than 120 mmHg with the presence of 
acute target organ damage (1-6). Hypertensive urgencies 
are diagnosed if there is a systolic blood pressure higher 
than 180 mmHg or a diastolic blood pressure higher than 
120 mmHg in an otherwise stable person without clinical 
or laboratory evidence of acute target organ damage (1-6). 
These persons need intensification of their antihypertensive 
drug therapy.
Patients with hypertensive emergencies include those 
who have a dissecting aortic aneurysm, acute pulmonary 
edema, acute myocardial infarction, unstable angina 
pectoris, acute renal failure, acute intracranial hemorrhage, 
acute ischemic stroke, hypertensive encephalopathy, 
eclampsia or pre-eclampsia, peri-operative hypertension, 
a pheochromocytoma crisis, and a sympathomimetic 
hypertensive crisis caused by use of cocaine, amphetamines, 
phencyclidine, or monoamine oxidase inhibitors or by 
abrupt cessation of clonidine or other sympatholytic 
drugs (1-6). These patients need effective and rapid 
acting medications administered intravenously to lower 
the elevated blood pressure safely, protect target organ 
function, ameliorate symptoms, reduce complications, 
and improve clinical outcomes (1-6). The 1-year mortality 
incidence of hypertensive emergencies is more than 79%, 
and the median survival is 10.4 months if these persons are 
not treated with antihypertensive drug therapy (7). 
The drug of choice in treating acute aortic dissection 
is  intravenous esmolol (1,5).  The loading dose is 
500–1,000 mcg/kg/min administered over 1 min followed 
by a 50 mcg/kg/min infusion rate. The maximum infusion 
rate is 200 mcg. Rapid and immediate reduction of 
blood pressure within 5 to 10 min is needed for patients 
with acute aortic dissection. The target blood pressure 
goal in these patients is a systolic blood pressure below 
120 mmHg. If the blood pressure remains elevated 
after beta blockade, a vasodilator such as intravenous 
nitroglycerin or nitroprusside may be administered.
The drugs of choice in treating a hypertensive emergency 
with acute pulmonary edema are intravenous nitroglycerin, 
clevidipine, or nitroprusside (1,2,5). Beta blockers are 
contraindicated in the treatment of acute pulmonary 
edema. Except for acute aortic dissection, the blood 
pressure in patients with hypertensive emergencies should 
be lowered within minutes to 1 h about 20% to 25% and 
then gradually to 160/100 mmHg within the next 2 to 6 h, 
and then cautiously to normal over the next 24 to 48 h (1). 
The initial infusion rate of intravenous nitroglycerin is 
5 mcg/min. The maximum infusion rate is 20 mcg/min. 
The initial infusion rate of intravenous sodium nitroprusside 
is 0.3 to 0.5 mcg/kg/min. The maximum infusion rate is 
10 mcg/kg/min. The initial infusion rate of intravenous 
clevidipine is 1–2 mg/h. The maximum infusion rate is 
32 mg/h.
Patients with an acute myocardial infarction or unstable 
angina pectoris and severe hypertension should be treated 
with intravenous esmolol (8). Intravenous nitroglycerin 
may also be administered if needed (8). The target blood 
pressure is less than 140/90 mmHg in patients with acute 
myocardial infarction or unstable angina pectoris who 
are hemodynamically stable (8). A blood pressure of 
less than 130/80 mmHg at hospital discharge should be 
considered (8). Caution should be used in lowering the 
blood pressure in these patients to avoid lowering the 
diastolic blood pressure to less than 60 mmHg as this may 
decrease coronary perfusion and aggravate myocardial 
ischemia (8).
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The drugs of choice in treating patients with a hypertensive 
emergency and acute renal failure are clevidipine, fenoldopam, 
and nicardipine (5). The initial infusion rate of intravenous 
fenoldopam is 0.1 to 0.3 mcg/kg/min. The maximum 
infusion rate is 1.6 mcg/kg/min. The initial infusion rate 
of intravenous nicardipine is 5 mg/h. The maximum 
infusion rate is 30 mg/h. In 104 patients with a hypertensive 
emergency with renal dysfunction treated in an emergency 
department with intravenous nicardipine or labetalol, within 
30 min of administration, the target systolic blood pressure 
was reached in 92% of patients treated with intravenous 
nicardipine versus 78% of patients treated with intravenous 
labetalol (9).
The drugs of choice in treating patients with a hypertensive 
crisis and eclampsia or pre-eclampsia are hydralazine, 
labetalol, and nicardipine (5,6). Angiotensin-converting 
enzyme inhibitors, angiotensin receptor blockers, direct renin 
inhibitors, and sodium nitroprusside are contraindicated 
in treating these patients. The maximum initial dose of 
intravenous hydralazine administered by slow intravenous 
infusion is 20 mg. This dose may be repeated every 4–6 h 
if needed. The initial dose of intravenous labetalol is 0.3 to 
1.0 mg/kg with a maximum initial dose of 20 mg followed 
by an intravenous infusion of 0.4 to 1.0 mg/kg/h up to 
3 mg/kg/h. The total cumulative dose is 300 mg. This dose 
can be repeated every 4 to 6 h if needed.
Drugs of choice used for treating postoperative surgical 
hypertension include administration of intravenous 
clevidipine, esmolol, nitroglycerin, and nicardipine 
(10,11). A systematic review and meta-analysis reported 
that clevidipine was the drug of choice for treating acute 
postoperative hypertension (10).
Drugs of choice for treating a hypertensive emergency 
caused by a pheochromocytoma or by an hyperadrenergic 
state caused by use of cocaine, amphetamines, phencyclidine, 
o r  monoamine  ox ida se  inh ib i to r s  o r  by  abrupt 
cessation of clonidine or other sympatholytic drugs are 
intravenous clevidipine, nicardipine, or phentolamine (1). 
The initial dose of phentolamine is an intravenous bolus 
dose of 5 mg. Additional bolus doses of 5 mg should be 
administered intravenously every 10 min as needed to 
reduce the blood pressure to the target level.
Intravenous enalaprilat may be administered to patients 
with a hypertensive emergency associated with a high 
plasma renin state (5,6,12). The initial dose of enaliprilat 
administered intravenously is 1.25 mg over 5 min. 
Additional doses of intravenous enaliprilat may be given 
up to 5 mg every 6 h as needed to reach the blood pressure 
target level.
A study randomized 104 patients with acute heart failure 
with hypertension to receive intravenous clevidipine versus 
standard of care intravenous antihypertensive drugs (87% 
intravenous nitroglycerin or nicardipine) (13). This study 
showed that the target blood pressure level was reached in 
71% of patients treated with clevidipine versus 37% of those 
receiving standard of care intravenous antihypertensive 
drugs. Clevidipine was also more effective than standard of 
care drugs in improving dyspnea at 45 min (13).
A study randomized 226 patients in an emergency 
department with a hypertensive emergency to treatment 
with intravenous  nicardipine versus  intravenous 
labetalol (14). Within 30 min, the target blood pressure 
level was reached in 91.7% of patients treated with 
intravenous nicardipine versus 82.5% of patients treated 
with intravenous labetalol (14). A subgroup of this study 
included 141 patients with signs and/or symptoms of target 
organ damage (15). Within 30 min, 91.4% of these patients 
randomized to intravenous nicardipine reached their 
target blood pressure level versus 76.1% of these patients 
randomized to intravenous labetalol (15). 
A Cochrane systematic review of pharmacological 
interventions for hypertensive emergencies included 
15 randomized controlled trials of 869 patients treated 
with seven drug classes (4). There were insufficient data to 
determine which antihypertensive drug is most effective 
in decreasing mortality and morbidity (4). Randomized 
clinical trials are needed to investigate initial and long-
term mortality outcomes in patients with hypertensive 
emergencies treated with different antihypertensive drugs. 
Randomized clinical trial data are also needed to determine 
how fast or how much the blood pressure should be lowered 
in a hypertensive emergency.
A study randomized 2,794 patients with a hypertensive 
emergency and acute intracerebral hemorrhage to a 
target blood pressure level of less than 140 mmHg 
within 1 h or to less than 180 mmHg within1 h using 
intravenous antihypertensive drugs chosen by the different 
physicians (16). The reduction of the systolic blood 
pressure to less than 140 mmHg was associated with a 13% 
borderline reduction in the primary outcome of death or 
major disability but with improved functional outcomes 
compared with reduction of the systolic blood pressure to 
less than 180 mmHg within 1 h (16). A meta-analysis of four 
randomized clinical trials including 3,315 patients with a 
hypertensive emergency and acute intracerebral hemorrhage 
demonstrated that intensive blood pressure lowering in these 
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patients to less than 140 mmHg was associated with a 13% 
borderline reduction in 3-month death or dependency (17). 
Intensive blood pressure lowering in acute cerebral 
hemorrhage also seems to reduce hematoma growth (18). 
The antihypertensive drug of choice for treating 
acute cerebral hemorrhage needs to be investigated by 
randomized clinical trials. Rapid acting, easily titratable 
drugs administered intravenously such as clevidipine, 
nicardipine, labetalol, and urapidil are reasonable first-line 
drugs for treating these patients (3). 
The 2013 American Heart Association/American 
Stroke Association acute ischemic stroke guidelines state 
that it is unknown what the blood pressure target level 
should be for patients with acute ischemic stroke or which 
antihypertensive drug should be recommended (19). These 
guidelines currently recommend not reducing the blood 
pressure during the initial 24 h of acute ischemic stroke 
unless the blood pressure is above 220/120 mmHg or there 
is a specific medical disorder that would benefit from blood 
pressure reduction. In patients with acute ischemic stroke 
eligible for acute reperfusion therapy, these guidelines 
recommend lowering the blood pressure to below 
180/110 mmHg before administering fibrinolytic therapy 
with intravenous labetalol or with intravenous nicardipine 
with consideration of other intravenous antihypertensive 
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